What Is MOTS-c? A Research Guide to the Mitochondrial Peptide

MOTS-c occupies a unique position in the peptide research landscape. Unlike most research peptides, which are synthetic creations designed in a lab, MOTS-c is an endogenous peptide -- meaning the human body produces it naturally. Its discovery in 2015 opened an entirely new chapter in our understanding of how mitochondria communicate with the rest of the cell.

This guide covers what MOTS-c is, how it works, what the published research shows, and how to source it for research at the best price.

---

What Is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded within mitochondrial DNA -- specifically the 12S rRNA gene. It was first identified by Dr. Changhan Lee's laboratory at the University of Southern California in a 2015 paper published in Cell Metabolism (PMID: 25738459).

What makes MOTS-c remarkable is its origin. The vast majority of peptides the body uses are encoded in nuclear DNA. MOTS-c is one of only a handful of known mitochondrial-derived peptides (MDPs), a class of signaling molecules produced directly by the mitochondrial genome. This finding challenged the long-held view that mitochondria were simply energy factories -- they are also active signaling organelles.

MOTS-c is classified as a metabolic peptide. It is not FDA-approved for any clinical use and is sold as a research chemical.

You can view the full MOTS-c research profile and compare vendor prices on PeptidePrices.

---

How Does MOTS-c Work?

MOTS-c operates through several interconnected metabolic pathways.

AMPK activation. MOTS-c activates AMP-activated protein kinase (AMPK), often described as the cell's master energy sensor. AMPK activation promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. This is the same pathway activated by exercise and the diabetes drug metformin, which is why MOTS-c has been called an "exercise mimetic" in some research contexts.

Folate-methionine cycle modulation. MOTS-c inhibits the folate cycle, which leads to accumulation of the metabolic intermediate AICAR, a potent AMPK activator. This mechanism provides an upstream explanation for its metabolic effects and distinguishes it from compounds that activate AMPK directly.

Nuclear translocation under stress. Research published in Nature Communications (2021) demonstrated that MOTS-c translocates from the cytoplasm to the nucleus during metabolic stress, where it regulates the expression of nuclear genes involved in antioxidant defense and glucose metabolism. This organelle-to-nucleus signaling represents a paradigm shift in cell biology.

Exercise-inducible expression. Circulating MOTS-c levels rise after physical exercise. This connection to physical activity, combined with observations that MOTS-c levels decline with age, has positioned it as a potential biomarker for metabolic fitness and aging.

---

What Does the Research Say?

The published research on MOTS-c spans cellular biology, animal models, and early human observations.

Metabolic regulation in animal models. The original 2015 Cell Metabolism study demonstrated that MOTS-c administration in mice prevented age-dependent and high-fat-diet-induced insulin resistance. Treated mice showed improved glucose tolerance and reduced fat accumulation compared to controls.

Exercise and aging. A 2021 Nature Communications study found that MOTS-c functions as an exercise-induced mitochondrial regulator. Circulating levels increase with physical activity, and administration in aged mice improved physical capacity and metabolic function.

Longevity associations. An Aging Cell study (2015, PMID: 26289118) found that certain MOTS-c variants are more prevalent in Japanese centenarians, suggesting a genetic link between MOTS-c biology and exceptional longevity.

Obesity and metabolic syndrome. Circulating MOTS-c levels have been found to be lower in obese children and adolescents (Pediatric Diabetes, 2018), and a clinical-stage MOTS-c analogue (CB4211) entered human trials for non-alcoholic fatty liver disease and obesity (NCT03998514).

Bone metabolism. Preclinical data has shown that MOTS-c suppresses bone loss in ovariectomized mouse models via AMPK signaling, suggesting potential relevance to osteoporosis research.

The full set of MOTS-c citations is available in the PeptidePrices research library.

---

MOTS-c Safety Profile

PeptidePrices assigns MOTS-c a safety rating of 7 out of 10. As an endogenous peptide -- one the human body already produces -- it carries a fundamentally different risk profile than purely synthetic compounds. Early human data from the CB4211 analogue trial showed acceptable tolerability in metabolic syndrome patients. No major safety signals have been identified in published research.

That said, long-term human safety data is limited, and no regulatory body has approved MOTS-c for clinical use. As with all research peptides, this information is for educational purposes only.

---

MOTS-c vs. Similar Compounds

MOTS-c is most often compared to other metabolic and longevity-oriented research peptides:

• AOD-9604 targets fat metabolism through a different pathway (lipolysis via the beta-3 adrenergic receptor). MOTS-c works upstream through AMPK and mitochondrial signaling.
• Humanin is another mitochondrial-derived peptide, but focused on neuroprotection and anti-apoptotic signaling rather than metabolic regulation.
• 5-Amino-1MQ is a small molecule NNMT inhibitor that targets fat metabolism through an entirely different mechanism (nicotinamide methylation) than MOTS-c's AMPK pathway.
• NAD+ precursors (NMN, NR) target mitochondrial function and aging through the NAD+/sirtuin axis, while MOTS-c operates through AMPK and direct nuclear gene regulation.

MOTS-c is distinctive because it is endogenous, exercise-responsive, and operates through a mitochondria-to-nucleus signaling axis that no other commercially available research peptide replicates.

---

Dosing in Research Settings

The following is for informational purposes only and does not constitute medical advice.

In published animal studies, MOTS-c has been administered at doses typically ranging from 5 to 15 mg/kg in mice, delivered via intraperitoneal injection. Human-equivalent dosing has not been established through clinical trials.

The CB4211 analogue trial used its own proprietary dosing protocol, which may differ from the native MOTS-c peptide. Because no standardized human research protocols exist for MOTS-c itself, any dosing information encountered online should be considered extrapolated and unvalidated.

---

Comparing MOTS-c Prices

MOTS-c pricing varies across vendors due to differences in synthesis complexity and sourcing. Some vendors offer MOTS-c in lyophilized vial form, while others sell pre-mixed solutions, making per-milligram normalization essential for fair comparison.

PeptidePrices tracks pricing across 19+ vendors and normalizes everything to a per-milligram basis.

See the live MOTS-c price comparison across all vendors.

If you are building a metabolic or longevity research protocol, the AI Stack Builder can help you explore compound combinations and estimate total costs.

---

Wrapping Up

MOTS-c represents a genuinely novel class of research compound -- an endogenous mitochondrial-derived peptide with demonstrated effects on metabolism, exercise physiology, and potentially aging itself. The science is still developing, particularly in humans, but the mechanistic data is compelling and the early clinical-stage work is promising.

If you are researching MOTS-c, start with the published literature, understand the legal landscape in your jurisdiction, and compare vendor prices before purchasing.

Compare MOTS-c prices across all vendors at PeptidePrices -- we track prices so you don't have to.

---

For research purposes only. Not for human consumption. Not medical advice. Always consult a qualified healthcare provider before making any health or supplementation decisions.